Research Advances in Developing Broader and Longer-Lasting Respiratory Vaccines

Researchers at Stanford Medicine and the University of Wisconsin have separately published findings on experimental vaccine approaches aimed at providing broader and more durable protection against respiratory pathogens. Both studies were primarily conducted in mice and highlight the potential for future vaccines that require fewer booster shots and offer wider protection.

These groundbreaking studies underscore the potential for a new generation of vaccines that could revolutionize protection against evolving respiratory viruses and common infections, reducing the need for frequent boosters and broadening immunity.

Stanford University's Universal Nasal Vaccine Research

On February 19, findings published in Science detailed an experimental universal vaccine developed by researchers at Stanford Medicine and collaborators. This vaccine, administered intranasally, provided broad protection in mice against a range of respiratory threats.

• Pathogen Coverage: Vaccinated mice exhibited protection against SARS-CoV-2, other coronaviruses, common hospital-acquired bacteria (Staphylococcus aureus and Acinetobacter baumannii), and house dust mites, a common allergen.
• Protection Duration: Protection observed in the lungs extended for several months.
• Comparative Outcome: Unvaccinated mice exposed to pathogens often experienced severe illness and mortality, whereas vaccinated mice showed minimal weight loss, survived, and had significantly reduced viral loads in their lungs.

The experimental vaccine functions by activating both the innate and adaptive immune systems in a coordinated manner. It mimics the communication signals exchanged between immune cells during an infection. T cells, involved in the adaptive response, are recruited to the lungs and send signals that maintain the activation of innate immune cells for an extended period, which typically subsides quickly. This sustained innate activity primes the immune system for a faster adaptive response. This enables the generation of virus-specific T cells and antibodies within three days, compared to approximately two weeks in unvaccinated subjects.

The next stage of research involves a Phase I safety trial in humans. Researchers estimate that a universal respiratory vaccine could be available within five to seven years, contingent on adequate funding. This development has the potential to reduce the need for multiple annual vaccinations for seasonal respiratory illnesses and to provide rapid protection against emerging pandemic viruses. The research team included scientists from Emory University School of Medicine, the University of North Carolina at Chapel Hill, Utah State University, and the University of Arizona. Funding was provided by the National Institutes of Health, the Violetta L. Horton Professor endowment, the Soffer Fund endowment, and Open Philanthropy.

University of Wisconsin's Research on Long-Lasting T-Cell Immunity

A separate study published on March 25 in Cell Reports by researchers at the University of Wisconsin School of Veterinary Medicine, led by Professor M. Suresh, identified a potential method for developing longer-lasting vaccines against respiratory viruses, including influenza and the virus causing COVID-19. This research focused on T cells, immune cells that eliminate virus-infected cells.

Unlike antibodies, which form the basis of many existing vaccines and can lose effectiveness as viruses mutate, T cells recognize more stable internal components of viruses. This characteristic offers a pathway to broader protection against evolving pathogens. A challenge in T cell-based vaccine development has been the relatively short lifespan of these cells.

The study, funded by the National Institutes of Health, investigated early immune signals activated within hours of vaccination. Researchers found that different inflammatory signals triggered by pathogens can program memory T cells. Using an experimental vaccine approach in mice, the team compared a virus-like immune signal with a bacterial-like immune signal. The virus-like inflammation resulted in memory T cells that declined rapidly, leading to a loss of protection. In contrast, the bacterial-like inflammation produced a distinct type of memory T cell that persisted longer and offered extended protection. These longer-lasting T cells displayed characteristics similar to stem cells, including persistence and regenerative capacity, and demonstrated adaptability by transitioning into a virus-fighting mode when vaccinated mice were exposed to infection.

These findings suggest a potential path toward vaccines that could require fewer booster shots and offer broader protection against various viral variants. The research also highlights the importance of delivering immunity at the site of infection, such as through nasal or lung-targeted vaccines for respiratory diseases. The current study was conducted in mice. The team plans to test the approach in nonhuman primates and in models that better represent the diversity of human immune systems. Future work will also investigate methods to guide immune cells to the lungs following traditional vaccination.